CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...
Brensocatib has demonstrated efficacy in reducing neutrophil serine protease activity and symptom burden in non-cystic fibrosis bronchiectasis. GLP-1 inhibitors show potential in managing obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results